Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland.
Robert ThomannStefan ZechmannNicola Alexander-DavidFrançois R JornayvazPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2020)
In patients with T2D on oral therapy and newly treated with basal insulin, Gla-300 improves glycemic control with a low risk of hypoglycemia and no increase of body weight. The results for Switzerland are consistent with those reported for the overall Toujeo-1 cohort and reveal that treatment targets and approaches slightly differ between both countries.